Premium
Dietary ellagic acid suppresses atherosclerotic lesion formation and vascular inflammation in apoE‐deficient mice
Author(s) -
Park SinHye,
Kang YoungHee
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.861.23
Subject(s) - ellagic acid , abca1 , inflammation , apolipoprotein e , abcg1 , cholesterol , lesion , chemistry , pharmacology , medicine , endocrinology , biochemistry , pathology , antioxidant , polyphenol , disease , transporter , gene
High levels of plasma LDL cholesterol are an important determinant of atherosclerotic lesion formation. The disruption of the process of cholesterol efflux or reverse cholesterol transport (RCT) of peripheral cells may promote atherogenesis. The aim of the current study is to investigate athero‐protective effects of ellagic acid administration on inflammatory atherosclerosis in apoE knockout (KO) mice fed athero‐control diet for 12 weeks. ApoE KO mice were divided into two groups and one group received 10 mg/kg ellagic acid orally during the same experimental periods. Ellagic acid supplementation to apoE KO mice reduced the number of eosinophils and basophils and improved serum lipid profile by decreasing atherosclerosis index and increasing HDL level. Treating with ellagic acid enhanced peritoneal macrophage expression of ABCA1 and ABCG1 responsible for cholesterol efflux associated with RCT. Atherosclerotic lesion formation in the aortas were suppressed by supplying ellagic acid, as evidenced by Oil red O staining. Moreover, plasma levels of soluble VCAM‐1 and C‐reactive protein, biomarkers of atherosclerotic inflammation, were diminished in ellagic acid‐supplementation. In addition, ellagic acid reduced aortic levels of VCAM‐1, MCP‐1, PECAM‐1, and F4/80. Therefore, dietary ellagic acid may be an athero‐protective agent retarding atherosclerotic lesion formation and vascular inflammation.